Physician profile
Soheab Ugradar
NPI 1891259420
$131,480.04
in general payments reported to CMS, 2019-2025
7 companies · $9,341 in 2025
The $9,341 reported for 2025 was more than what 90% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.36 · 2021: $61.84 · 2022: $2,701 · 2023: $98K · 2024: $22K · 2025: $9,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $118K · Travel and Lodging: $8,509 · Food and Beverage: $1,098 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $117,991.67 |
| Travel and Lodging | $8,509.19 |
| Food and Beverage | $1,098.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,075.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $100,442.72 | 2022-2023 | Tepezza |
| Amgen INC. | $29,139.62 | 2024-2025 | Tepezza |
| Vertex Pharmaceuticals Incorporated | $1,241.67 | 2025 | |
| Abbvie INC. | $316.22 | 2024-2025 | |
| Argenx US, INC. | $234.61 | 2025 | |
| Merz Pharmaceuticals, LLC | $61.84 | 2021 | |
| Merz North America, INC. | $43.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soheab Ugradar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.